Neurogene (NGNE) Net Equity Issued and Repurchased (2025)

Neurogene (NGNE) posted Net Equity Issued and Repurchased of $20.6 million for Q4 2025.

Neurogene (NGNE) Net Equity Issued and Repurchased (2025) Analysis & Trends

Neurogene's Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $20.6 million for Q4 2025.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $20.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.6 million (changed N/A YoY) and the FY2025 annual result came in at $30.4 million, changed N/A from the prior year.
Net Equity Issued and Repurchased was $20.6 million for Q4 2025 at Neurogene.
Across five years, Net Equity Issued and Repurchased topped out at $20.6 million in Q4 2025 and bottomed at $20.6 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	163.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	141.90 Mn
10	Neurogene	17.50 Mn	17.50 Mn	-	-

Download Data

Date	Value
Dec 31, 2025	20.58 Mn
Dec 31, 2025	20.58 Mn